SSY GROUP(02005.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at HKD 320.32 million, YoY increase of 12.99%
NewTimeSpace News: August 26, 2026, SSY GROUP(02005.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at HKD 2.36 billion, increased by 9.94% YoY; Net Profit stood at HKD 326.59 million, YoY increase of 12.54%; Profit Attributable to Shareholders stood at HKD 320.32 million, YoY increase of 12.99%; Basic Earnings Per Share (EPS) stood at HKD 0.11.
In terms of profitability, SSY GROUP Gross Profit changed from HKD 890.35 million in the same period last year to HKD 972.42 million in the current period, increased by HKD 82.06 million; gross profit margin changed from 41.47% in the same period last year to 41.19% in the current period, decreased by 0.27 percentage points; net profit changed from HKD 290.2 million in the same period last year to HKD 326.59 million in the current period, increased by HKD 36.4 million; net profit margin changed from 13.52% in the same period last year to 13.84% in the current period, increased by 0.32 percentage points.
In terms of earnings quality, SSY GROUP Operating Profit changed from HKD 370.86 million in the same period last year to HKD 445.3 million in the current period, increased by HKD 74.44 million; Operating Profit Margin changed from 17.27% in the same period last year to 18.86% in the current period, increased by 1.59 percentage points.
In terms of financial soundness, SSY GROUP Debt-to-Asset Ratio changed from 40.61% in the same period last year to 39.58% in the current period, decreased by 1.03 percentage points; Total Equity changed from HKD 7.597 billion in the same period last year to HKD 8.136 billion in the current period, increased by HKD 538.63 million; Current Liabilities changed from HKD 1.63 billion in the same period last year to HKD 2.81 billion in the current period, increased by HKD 1.18 billion; Quick Ratio changed from 2.4 in the same period last year to 1.43 in the current period, decreased by 0.97 percentage points.
In terms of R&D investment focus, SSY GROUP R&D Expenses changed from HKD 136.26 million in the same period last year to HKD 96.97 million in the current period, decreased by HKD 39.29 million; R&D to Total Revenue Ratio changed from 6.35% in the same period last year to 4.11% in the current period, decreased by 2.24 percentage points.
NewTimeSpace Disclaimer:All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- SSY GROUP (02005.HK): Obtains production registration approval for sodium ozagrel injection, achieving full dosage form coverage
- SSY GROUP (02005.HK): Vitamin K1 Injection obtains NMPA drug production registration certificate, deemed to pass consistency evaluation
- SSY GROUP (02005.HK): Four Products Receive NMPA Drug Manufacturing Registration Approvals, Deepening Infusion Therapy and Ophthalmology Portfolio
- SSY Group (02005.HK): All 16 Specifications of 13 Pharmaceutical Varieties Proposed to Be Selected in the 12th National Centralized Drug Procurement
- SSY Group (02005.HK): Cimetidine Injection and Acetylcysteine Solution for Inhalation Obtain Manufacturing Registration Approvals